Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two groups of patients treated by short (Milan) and long (Newcastle) haemodialysis were compared for incidence of symptoms and biochemical control. Short dialysis corrected urea and creatinine as well but control of potassium and phosphate were similar. The only apparent penalties to be paid by short dialysis patients were a higher incidence of itching, tingling or numbness, impairment of vibratory sense and difficulty in controlling blood pressure. The short dialysis group had higher haemoglobin and less dyspnoea, muscle weakness and dizziness after dialysis.
Proc Eur Dial Transplant Assoc 1976
PMID:A comparison of short and long haemodialysis. 93 42

Treatment with rHuEpo can eliminate many symptoms that had been attributed to uremia. Repetitive punctures in children undergoing three times weekly subcutaneous (SC) rHuEpo can result in noncompliance with the therapeutic regimen. The aim of this study was to evaluate the efficacy of once weekly SC injection of rHuEpo in children with end-stage renal disease (ESRD) on CAPD. Six children (5 males, 1 female, mean-age: 6.0 years, range: 0.5 to 15.8 years) with ESRD on CAPD were treated with a regimen of rHuEpo 150 U/Kg/week SC for 12 weeks. All patients received oral iron supplementation. All children had improved appetite and well-being. The adolescents showed an increased ability to engage in regular activities. The hematocrit increased from 20.3 +/- 1.2% to 31.7 +/- 3.8% in 12 weeks. The mean weekly increase in hematocrit was 0.95 +/- 0.34%. There was no significant differences in iron indice prior to and during rHuEPO treatment. Side effects related to rHuEpo included transient pain at the site of injection in all, pruritus at the site of injection in 1 child, hyperphosphatemia in 1 infant, iron relative deficiency in 2 children and an asymptomatic increase in blood pressure in 1 hypertensive child. None of the 5 normotensive patients developed hypertension. We concluded that once weekly 150U/kg SC rHuEpo is effective in correcting anemia in children on CAPD. This regimen results in few side effects, decreases the cost of treatment and produces less distress to the patients by avoiding repetitive injections.
Adv Perit Dial 1992
PMID:Once weekly subcutaneous administration of recombinant erythropoietin in children treated with CAPD. 136 43

Peritonitis following urticaria on two occasions in a 46-year-old white female treated with CAPD for nine years is reported. On both occasions an episode of urticaria and pruritus occurred 24 hr before the dialysate became cloudy, and the patient experienced abdominal pain, nausea, and vomiting. The culture of the peritoneal dialysis effluent grew gamma Streptococcus with the first episode. To our knowledge this is the first report of CAPD peritonitis preceded by urticaria where the skin findings were most likely related to the peritoneal infection.
Perit Dial Int 1992
PMID:Streptococcus peritonitis with urticaria. 158 83

Serum indoxyl sulphate, which is markedly accumulated in haemodialysis patients, cannot be removed efficiently by haemodialysis due to its albumin-binding property. To determine whether an oral adsorbent (AST-120) can decrease its serum concentration, AST-120 was administered to haemodialysis patients. The patients given AST-120 showed significantly reduced serum concentration of indoxyl sulphate as compared to control haemodialysis patients, even though the serum concentrations of urea nitrogen and creatinine did not decrease significantly in the patients treated with AST-120. The haemodialysis patients with generalised pruritus showed an amelioration of itching after administration of AST-120. These results showed that AST-120 was effective in reducing the serum concentration of albumin-bound indoxyl sulphate in haemodialysis patients by adsorption of indole, a precursor of indoxyl sulphate, in the intestines, and that it relieved itching in haemodialysis patients with generalised pruritus.
Nephrol Dial Transplant 1991
PMID:Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. 190 99

The effect of oral Cimetidine compared to a classic antihistaminic and to a placebo was evaluated, under the double hypothesis of its anti-PTH and anti-pruritus action, in a population of patients recently included in Hemodialysis that were asked about the incidence and intensity of pruritus according to a scored questionnaire made for this purpose. No different efficacy of Cimetidine versus the antihistaminic classic and the placebo was observed in our study.
J Dial 1980
PMID:Dialysis pruritus: effect of cimetidine. 720 12

The pathogenesis of pruritus in patients undergoing chronic haemodialysis is unknown. Dryness of the skin is common in uraemic patients, and a correlation between xerosis and pruritus has been reported. Transepidermal water loss (TEWL) is a measure of cutaneous barrier function and also reflects skin water content. In this study the transepidermal water loss was measured at four sites pre- and postdialysis in 20 subjects undergoing chronic haemodialysis and in 16 healthy controls. Patients were weighed before and after dialysis and blood was taken for measurement of urea, creatinine, calcium, magnesium, phosphate and haemoglobin. All patients had parathyroid hormone measured within 3 months of the assessment. There was no significant difference in TEWL between patients and controls, with control values in general being between pre- and postdialysis rates of TEWL, and no correlation between TEWL and the presence or absence of pruritus. There was no significant differences between the pruritic and non-pruritic patients for any of the biochemical markers measured. Finally there was no significant correlation between the percentage water loss and TEWL. These findings indicate that pruritus of chronic haemodialysis is not related to abnormalities of cutaneous permeability.
Nephrol Dial Transplant 1994
PMID:Relationship between pruritus, transepidermal water loss, and biochemical markers of renal itch in haemodialysis patients. 781 95

Pruritus is one of the most common complaints of haemodialysed patients. However, its pathogenesis remains unclear. Dryness of the skin and the effects of pH changes on the nerve endings in the skin have been suggested as related factors. In the present study we measured skin pH using a skin pH meter and skin moisture using a corneometer at four different sites in 41 haemodialysis patients, before and after dialysis, and in 40 healthy controls. Thirty patients (73%) complained of pruritus, six severe constant, 12 moderate and 12 mild. Skin surface pH was higher in patients than in controls in the upper back (5.54 +/- 0.14 versus 5.22 +/- 0.08, P < 0.02), forearm (5.5 +/- 0.1 versus 5.13 +/- 0.1, P < 0.01) and forehead (5.35 +/- 0.08 versus 5.04 +/- 0.07, P < 0.004), whereas there was no difference in the axilla. Haemodialysis had no effect on skin pH, and there was no correlation with blood pH, blood bicarbonate and serum electrolytes. There was no correlation between skin surface pH and pruritus. Skin moisture was lower in haemodialysis patients than in controls in the forehead and axilla. There was no correlation with pruritus. Skin surface pH is higher in haemodialysed patients than in healthy controls in most areas of the body, despite the fact that these patients have a decreased blood pH. Thus, the skin pH is not related to systemic acid-base balance. It is possible that the uraemic state affects the ability of the dermal cells to secrete acid, making the skin more susceptible to bacterial and fungal infections.(ABSTRACT TRUNCATED AT 250 WORDS)
Nephrol Dial Transplant 1993
PMID:Skin surface pH, moisture, and pruritus in haemodialysis patients. 797 Jan 10

A crossover study to compare the effects of seven different dialysers on intradialytic symptoms in 37 patients during dialysis with acetate-containing dialysate was performed at five centres in four countries. The same manufacturing lot of each dialyser and of blood line sets were used by all centres. The same clinical data (duration of dialysis, blood pressure, weights, temperature, drugs, symptoms, and treatments) and technical data (blood flow, dialyser clearance, and ultrafiltration rate) were collected. Kt/V for urea was used to determine dialysis prescribed. Intradialytic symptoms and signs were measured hourly or when observed by staff using the haemodialysis treatment form (see Introduction). After each week of treatment with a particular dialyser, patients completed a questionnaire relating to the presence and severity of symptoms. (Only presence or absence of symptoms are presented.) Wide differences in dialysis duration and blood flow between centres were noted. These may have contributed to the differences between centres in relationship to staff reported responses to different dialyser: Dialysers with the lowest incidence of both signs and symptoms and of chest pain, back pain, and itching (arbitrarily designated bioincompatibility symptoms) were the Duo-Flux and Filtral, with the G120 M, the CD 4000, and the T 150 having the highest incidence. By patient questionnaire the most biocompatible dialysers were the T 150, F 60, and the Filtral, with the most symptom producing being the G120 M and the G10-3N. Perceptions of symptoms between patients and staff differed substantially overall and between centres. Hypersensitivity reactions were noted in two patients, both occurring with cuprammonium cellulose hollow-fibre dialysis, despite adherence to manufacturers' instructions concerning saline priming and removal. Both patients showed antibody titres greater than 1:160 against ethylene oxide-HSA. Ethylene oxide was not detected (limit of detection 1 part per million) in dialysers, blood line sets, or fistula needles. The study suggests that dialysis symptom reporting is complicated by individual perceptions, staff reactions, and the efficiency of recording. In this study ethnic and cultural differences must be added to the haemodynamic differences and other prescription-related elements in influencing symptoms. Despite these problems a hierarchy of dialyser-related symptoms and signs could be discerned which largely paralleled laboratory findings of biocompatibility. Future comparative studies relating symptomatology to membrane and dialyser structure should consider the variables identified as influencing symptoms and their reporting.
Nephrol Dial Transplant 1993
PMID:Relationship between dialyser type and signs and symptoms. 827 50

Nineteen patients treated by continuous ambulatory peritoneal dialysis (CAPD) were studied according to clinical outcome parameters: insomnia, asthenia, pruritus, arterial hypertension, anorexia, nausea and/or vomiting, anemia, and rate of hospitalization. Using clinical scores, three groups were defined: poor clinical outcome (P), intermediate (I), and good (G). The quantity of treatment by PD was evaluated monthly with urea kinetic tests (weekly Kt/V, weekly urea clearance/1.73 m2 of body surface area (BSA), index of dialysis by Teehan), and with the weekly creatinine clearance/1.73 m2 of BSA. The metabolic index was analyzed: normalized protein catabolic rate (NPCR), serum albumin (Alb) and prealbumin, and reabsorption of glucose. There was good correlation between clinical scores and quantity of dialysis. The Alb was lower in group P. Group G was differentiated from group I and from group P by quantification tests and NPCR, with lower levels as follows: weekly Kt/V = 2.06, urea clearance 70 L/week/1.73 m2, index of dialysis = 0.87, and creatinine clearance = 60 L/week/1.73 m2. We conclude that the qualitative clinical approach is not sufficient to predict deleterious signs, and the quantitative approach is predictive of the good clinical outcome and good nutritional status. We think that levels proposed to now are insufficient, and we suggest the following: weekly urea clearance > 70 L, weekly Kt/V > 2, weekly creatinine clearance > 60 L, and index of dialysis > 0.85.
Perit Dial Int 1993
PMID:Quantification of adequacy of peritoneal dialysis. 839 69

To study the prevalence and pathogenesis of uremic pruritus, CAPD and HD patients were asked to complete a questionnaire. The replies were quantitated based on numerical scales, and the results were compared with various hematological and biochemical parameters, underlying disease, and duration of dialysis. There were 113 CAPD patients (63 males and 50 females), mean age 60 (range 20-84) years, average time on CAPD 20 (range 1-163) months and 76 HD patients (44 males and 32 females) mean age 57 (range 23-81) years, mean time on HD 44 (range 2-242) months. Replies to questions were evaluated and graded by the same investigator who did not know the patients. Pruritus was present in 70 (62%) CAPD patients (64% in females and 60% in males p = NS) and in 41 (54%) HD patients (69% in females and 43% in males, p = 0.025). Before starting dialysis pruritus was present in 30% CAPD patients and 28% HD patients. Pruritus was graded as mild, moderate and severe; the distribution was 58.6%, 34.3%, and 7.1% (CAPD) and 43.9%, 41.5%, and 14.6% (HD), respectively. Dry skin was reported by 73% CAPD patients and 72% HD patients. This xeroderma was correlated with the severity of pruritus and was also present in 65% CAPD and 48.5% HD patients without pruritus. Patients with pruritus were older than those without pruritus both for CAPD (63 vs 54 years, p = 0.004) and HD (61 vs 51 years, p = 0.003). A significant correlation was observed only between pruritus score and age for CAPD patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Perit Dial Int 1993
PMID:Pruritus in continuous ambulatory peritoneal dialysis and hemodialysis patients. 839 56


1 2 3 4 Next >>